Background and Purpose-There have been few recent population-based studies reporting the incidence (first ever) and attack rates (incident and recurrent) of transient ischemic attack (TIA). Methods-The fourth Auckland Regional Community Stroke study (ARCOS IV) used multiple overlapping case ascertainment methods to identify all hospitalized and nonhospitalized cases of TIA that occurred in people ≥16 years of age usually resident in Auckland (population ≥16 years of age is 1.12 million), during the 12 months from March 1, 2011. Approximately two thirds of people were known to be hypertensive or were being treated with blood pressure-lowering agents, half were taking antiplatelet agents and just under half were taking lipid-lowering therapy before the index TIA. Two hundred ten (27%) people were known to have atrial fibrillation at the time of the TIA, of whom only 61 (29%) were taking anticoagulant therapy, suggesting a failure to identify or treat atrial fibrillation. 
T
here have been few recent population-based incidence studies of transient ischemic attack (TIA). [1] [2] [3] [4] Such studies are difficult to perform because TIA diagnosis relies on expert clinical assessment, and they require regular and comprehensive case ascertainment from multiple overlapping sources of information in the whole population. 5 Many of the earlier TIA incidence studies were performed before the widespread use of medications to lower cholesterol levels and blood pressure and surgical intervention in patients with significant internal carotid artery stenosis. Even fewer population-based studies have examined the effect of ethnicity on the burden of TIA in the same community. 6, 7 We examined the incidence of TIA in a large populationbased TIA and stroke incidence study. The aim was to determine the burden of TIA in an ethnically diverse community in an era of aggressive primary and secondary vascular risk factor management.
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Methods
The fourth Auckland Regional Community Stroke study (ARCOS IV) utilized a population-based register of first ever, or first-ever and recurrent, TIA and stroke events, during the 12 months from March 1, 2011, in people aged ≥16 years in the resident population of the Auckland region (in 2011-2012, the population aged ≥16 years was 1 119 192). 8 Detail on the ARCOS IV methodology of case ascertainment has been provided elsewhere. 8 In brief, all new hospitalized and nonhospitalized cases of TIA and stroke were identified using multiple overlapping methods of case ascertainment. 9, 10 Daily checks were made of all public hospitals, emergency departments, hospital discharge registers, and computed tomography/magnetic resonance imaging records; weekly checks of all private hospitals, rest homes, and community health services (general practices, hospital outpatient clinics, and rehabilitation centers); monthly checks of coroner/autopsy records; and quarterly checks of New Zealand Health Information Service data and death certificates (from the Registrar of Births, Deaths, and Marriages).
The study population is ethnically diverse comprising those of European origin (56% of the population), Māori/Pacific (25%; the indigenous people of New Zealand and people originating from the Pacific Islands, ethnically Polynesian) and Asians/Other (19%). 11 The region has been consistently served by 4 large public acute care hospitals, 2 main private medical care hospitals, and many long-stay residential care facilities. The Regional Ethics Committee approved the study.
Trained clinical researchers and nurses undertook face-to-face interviews with patients or the next-of-kin where necessary, as soon as possible after notification of TIA. A structured questionnaire was used to obtain information about demographics, clinical features, investigations, management, and health status (Appendix I in the online-only Data Supplement). Both known and newly diagnosed risk factors were documented. Ethnic group was defined by self-identification and prioritized as European, Māori/Pacific, and Asian/Other using corresponding New Zealand census definitions. Information on ethnic group was not available in 12 study participants who were excluded from the ethnicity analyses.
TIA was defined as an acute loss of focal cerebral or ocular function with symptoms lasting <24 hours, and that after adequate investigation was presumed to be because of embolic or thrombotic vascular disease, as previously defined. 6 Patients with isolated vertigo, diplopia, bilateral blindness, drop attacks, nonfocal symptoms, and features suggesting migraine, epilepsy, or transient global amnesia, were excluded. Brain imaging was used to exclude disorders mimicking TIA. To enable comparison with earlier studies, brain imaging was not used to reclassify patients with transient symptoms and evidence of acute infarction as stroke and not TIA. Therefore, this sample likely includes some patients with minor stroke using a tissue-based definition of cerebral infarction. All first-ever and recurrent new TIAs (any new TIA event 28 days after the index event) during the study period were recorded.
A diagnostic committee of study physicians (P.B., V.F., and Y.R.) classified all TIA cases using medical history, clinical and laboratory findings (Appendix I in the online-only Data Supplement). The diagnostic committee optimized case ascertainment by meeting regularly to review the clinical features, medical records, and imaging results of all recently referred patients. Difficult cases were classified by consensus. Only patients in whom the diagnostic committee agreed met the above criteria were included.
Crude annual age-, sex-, and ethnic-specific annual incidence (first-ever-in-a-lifetime events) and attack (first ever and recurrent events) per 100 000 people with 95% confidence intervals (CIs) were calculated assuming a Poisson distribution. Age-standardized rates were derived by the direct method with World Health Organization (WHO) world population as the reference. 12 To facilitate comparisons with previous studies, summary rates were also age standardized to the European population. 13 Ethnic-specific rates were calculated using the proportion of residents belonging to each of the specific ethnic groups.
For categorical variables, statistical significance of trends was assessed using the Cochrane-Armitage trend test; and for continuous Ischemic heart disease 194 (25) 152 (25) 20 (21) 22 (29) 0.484
Previous stroke 172 (23) 129 (22) 24 (27) 19 (26) 0.418
Previous TIA † 185 (25) 154 (26) 20 (23) 11 (16) 0.132
Current smoker 51 (7) 36 (6) 12 (14) 3 (4) 14 and it used the 3 main sources of notification: hospital, general practitioner, and other sources. P<0.05 was considered statistically significant in all analyses.
Results
There were 785 people who presented with TIA (402 [51.2%] women, mean [SD] age 71.5 [14] years), of whom 732 had a first-ever TIA and 53 had a recurrent TIA (Table 1 ). There were 614 (78.2%) people who identified as European, 84 (10.7%) as Māori/Pacific, and 75 (9.6%) as Asian/Other. Six hundred forty-five (82%) people were seen in an acute hospital setting such as an emergency department or acute medical assessment unit, and most of the remainder were seen in an outpatient clinic setting. The estimated number of missing cases was low as determined by the capture-recapture analysis (13/785; 1.5%). Brain imaging was obtained in 594 (76%) people within 24 hours and 621 (79%) within 28 days of symptom onset. TIA was diagnosed solely on the basis of clinical presentation by the diagnostic committee in those people in whom brain imaging was not obtained.
Before presentation, 172 (23%) of 785 people were known to have had a stroke. Five hundred thirteen (65%) were known to have hypertension (with 61% treated with antihypertensive therapy), and an additional 57 (7%) had a first blood pressure recording >140/90 mm Hg. Three hundred sixty-nine (47%) people had been diagnosed as having elevated lipids, with a similar proportion (45%) treated with lipid-lowering therapy. Four hundred fourteen (53%) were taking antiplatelet agents. Two hundred ten (27%) were known to have atrial fibrillation, of whom only 61 (29%) were taking anticoagulant therapy at the time of the TIA. An additional 69 (9%) were first diagnosed as having atrial fibrillation at presentation.
There were ethnic differences in vascular risk factors. Māori/Pacific and Asian/Other people had double the rates of known diabetes mellitus at presentation compared with Europeans, and there was a trend for Māori/Pacific people to be less likely to be known to have elevated lipids. There was 
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September 2016 also a trend for Māori/Pacific people to be more likely to be seen in an acute hospital setting than the other ethnic groups. The annual incidence of TIA was 40 (95% CI, 36-43) per 100 000 people, age standardized to the WHO world population ( Table 2 ). The annual TIA incidence rates increased with age in all groups and were similar in men (41, 95% CI, 36-46) and women (38, 95% CI, 34-43). When age standardized to the European population to enable comparisons with earlier studies, the annual incidence of TIA was 73 (95% CI, 67-80) per 100 000 people per year.
The annual attack rate (incident and recurrent) of TIA was 63 (95% CI, 59-68) per 100 000 people, age standardized to the WHO world population. The annual attack rates also increased with age in all groups and were similar in men (69, 95% CI, 63-76) and women (58, 95% CI, 53-64). Ethnic differences were also seen with Asian/Others having almost half the incidence and attack rates than the other 2 ethnic groups (Table I in 
Discussion
This study found that during a 12 month period, there were 40 first-ever TIAs (95% CI, 36-43), and an acute cerebrovascular service could expect 63 (95% CI, 59-68) people with first-ever or recurrent TIA per 100 000 people at risk. When standardized to the European population, the annual TIA incidence was 73 (95% CI, 67-80). This was higher than that found in the Oxford Vascular Study (OXVASC) study, where the annual TIA incidence was 58 (95% CI, 46-69) per 100 000 people, 15 but in the middle of the range when compared with other populations studied since 2000 (Figure) . [1] [2] [3] [4] 6, [16] [17] [18] [19] [20] This likely reflects higher stroke incidence in our population compared with other developed countries. 21 Ethnic differences were seen with Asian/Other having half the incidence of TIA compared with the other ethnic groups. This difference may be related to the large influx of younger, presumably generally healthy, Asian immigrants into New Zealand during the past 2 decades. 11 TIA incidence rates in Māori/Pacific were slightly, albeit not statistically significantly, lower than that in European people. This finding is at odds with the ARCOS IV stroke incidence study where Māori/Pacific had higher age-standardized stroke incidence rates. 8 We speculate that this discrepancy between TIA and stroke incidence may be because of a failure to seek medical attention for transient neurological symptoms in these ethnic groups. 22 A large number of individuals were identified as having, and were taking treatment for, vascular risk factors. Approximately two third were known to be hypertensive and were being treated with blood pressure-lowering agents, half were taking antiplatelet agents, just under half were taking lipid-lowering therapy, and there were low current tobacco smoking rates. However, what seems to have been aggressive management of vascular risk factors did not seem to have had a marked impact on TIA incidence, when compared with earlier studies. A possible explanation is the low use of anticoagulant therapy. Just over two thirds (71%) of the patients known to have atrial fibrillation at the time of presentation were not being treated with oral anticoagulants. This finding is not isolated to our cohort with low rates of anticoagulation therapy noted in other populations of stroke and in patients with TIA presenting with atrial fibrillation. 23, 24 Education strategies that focus on increasing community and physician awareness of the need for guidelinebased atrial fibrillation treatment may lead to reductions in the number of people presenting with TIA and stroke Most patients with TIA were seen in hospital emergency departments or were admitted to hospital. The 4 public hospitals serving the study region have acute medical assessment units where patients can be admitted and assessed urgently, with outpatient TIA clinics used for lower risk patients. This high rate of inpatient hospital care is in contrast to the OXVASC study where almost two third of patients were managed as outpatients. 15 Rapid access TIA clinics improve outcomes and are cost effective but the provision of such clinics may be challenging in some healthcare settings. [25] [26] [27] There is unlikely to be a one size fits all solution with the provision of TIA services varying depending on local factors.
This study has several strengths. ARCOS IV was the fourth in a series of ideal population-based stroke incidence studies carried out every decade since 1981. There was prospective case ascertainment in a well-defined population with multiple overlapping sources of information and using standard WHO definitions. New Zealand has a public health system available to all residents, with provision of a government part subsidy for primary care practice visits and free hospital care, reducing but not eliminating barriers to patients seeking medical care.
This study also has several limitations. Most notifications came from medical practitioners or hospitals with few from other sources. It is likely that many people with transient neurological symptoms fail to seek medical care and were, therefore, not identified. This is a problem that faces all TIA incidence studies. In addition, only people who met strict study diagnostic criteria were included. The number of patients referred with suspected TIA may be up to 6× greater than those with definite TIA and needs to be borne in mind when planning acute cerebrovascular services. 15 In conclusion, the incidence of TIA in this study sits in the middle range when compared with earlier reports from a range of other countries. The high use of antihypertensive, antiplatelet, and lipid-lowering therapy is reassuring. However, management of atrial fibrillation remains a problem. Most patients who were known to have atrial fibrillation at the time of the TIA were not being treated with anticoagulants. We speculate that comprehensive education programs for medical practitioners and patients, and increased use of newer fixed dose oral anticoagulants, may lead to reductions in TIA incidence.
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